Michel D. Wissing - Concepedia

Author

Michel D. Wissing

Also Known As

Elke M. den Boogert, M Wissing, M. Wissing, MICHEL D. WISSING, May Wissing, Michael Wissing, Michel D Wissing, Michel D. Wissing, Michel D. Wissing (363968), Michel Wissing

Publications

Citations

H-Index

Concepts

All Affiliations

McGill University Leiden University Medical Center Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center University Medical Center Utrecht

About

Michel D. Wissing is an author at McGill University specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	313
2	Cell Biology	4	4	194
3	Engineering	1	1	37
4	Public Health	1	1	16
5	Social Sciences	1	1	19

Michel D. Wissing

Publications

791

Citations

H-Index

Page 1

	Year	Citations
Downregulation of Homologous Recombination DNA Repair Genes by HDAC Inhibition in Prostate Cancer Is Mediated through the E2F1 Transcription Factor Sushant K. Kachhap, Nadine Rosmus, Spencer J. Collis, PLoS ONE	2010	152
Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment John T. Isaacs, Lizamma Antony, Susan L. Dalrymple, Cancer Research Colon Tumor XenograftsChemoprevention StrategyImmunologyHistone Deacetylase Hdac4Cell Death	2012	110
Does hormonal therapy for fertility preservation affect the survival of young women with early‐stage endometrial cancer? Zoë R. Greenwald, Lina Huang, Michel D. Wissing, Cancer	2016	52
CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate‐resistant prostate cancer previously treated with docetaxel Michel D. Wissing, Jules L.L.M. Coenen, Pieter van den Berg, International Journal of Cancer	2014	43
Under‐representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993‐2013 Michel D. Wissing, Paul G. Kluetz, Yang‐Min Ning, Cancer	2014	40
Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors Madeleine S.Q. Kortenhorst, Michel D. Wissing, Ronald Rodríguez, Epigenetics Histone DeacetylasesEngineeringGenomic ResponseEpigeneticsTumor Biology	2013	37
Targeting prostate cancer cell lines with polo‐like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors Michel D. Wissing, Janet Mendonca, Madeleine S.Q. Kortenhorst, The FASEB Journal	2013	34
Combining the pan‐aurora kinase inhibitor <scp>AMG</scp> 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer Channing J. Paller, Michel D. Wissing, Janet Mendonca, Cancer Medicine OncologyAntitumor ActivityMedicineHistone Deacetylase InhibitorsCancer Cell Biology	2014	30
Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer: Results of a Compassionate Use Program in The Netherlands Michel D. Wissing, Inge M. van Oort, Winald R. Gerritsen, Clinical Genitourinary Cancer UrologyOncologyCompassionate Use ProgramCancer ManagementPharmacotherapy	2013	29
CA‐125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high‐grade ovarian cancer Roy Kessous, Michel D. Wissing, Sabrina Piedimonte, Acta Obstetricia Et Gynecologica Scandinavica	2020	27

Page 1